GLP1R and urinary bladder carcinoma: The analysis, which included data from 1,276,762 patients prescribed various antidiabetic medications, revealed that GLP-1 receptor agonist use was associated with a higher risk of bladder cancer compared to SGLT2 inhibitors (HR 1.47), kidney cancer compared to metformin (HR 1.45), and prostate cancer compared to insulin (HR 1.32) [5].